文章摘要
秦 策,王 洋,吴媛媛,张 冬,史 英,刘 欣.雄激素去势治疗联合多西他赛对晚期前列腺癌患者血清hk2、miR-221及NF-κB水平的影响[J].,2021,(5):987-991
雄激素去势治疗联合多西他赛对晚期前列腺癌患者血清hk2、miR-221及NF-κB水平的影响
Effects of Androgen Castration Combined with Docetaxel on Serum Levels of hk2, miR-221 and NF-κB in Patients with Advanced Prostate Cancer
投稿时间:2020-07-28  修订日期:2020-08-24
DOI:10.13241/j.cnki.pmb.2021.05.040
中文关键词: 晚期前列腺癌  雄激素去势治疗  多西他赛  人激肽释放酶  微核糖核酸-221  核转录因子-κB
英文关键词: Advanced prostate cancer  Androgen castration therapy  Docetaxel  Human kallikrein  MicroRNA-221  Nuclear transcription factor-κB
基金项目:河北省沧州市科技计划项目(141302095)
作者单位E-mail
秦 策 沧州市中心医院肿瘤内科 河北 沧州 061000 mantfwd@163.com 
王 洋 沧州市中心医院肿瘤内科 河北 沧州 061000  
吴媛媛 沧州市中心医院肿瘤内科 河北 沧州 061000  
张 冬 沧州市中心医院肾内科 河北 沧州 061000  
史 英 沧州市中心医院肿瘤内科 河北 沧州 061000  
刘 欣 河北医科大学附属第四医院放疗科 河北 石家庄 050019  
摘要点击次数: 655
全文下载次数: 322
中文摘要:
      摘要 目的:研究雄激素去势治疗联合多西他赛对晚期前列腺癌患者血清人激肽释放酶(hk2)、微核糖核酸-221(miR-221)及核转录因子-κB (NF-κB)水平的影响。方法:选择我院2014年9月~2016年1月收治的80例晚期前列腺癌患者为研究对象,依据随机数字表法分为对照组和实验组,各40例。对照组采用单纯雄激素去势治疗,实验组采用雄激素去势治疗联合多西他赛,对比两组临床疗效,治疗前后血清前列腺抗原(PSA),hk2、miR-221及NF-κB水平,生活质量,不良反应和生存情况。结果:治疗后,实验组总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清PSA、hk2、miR-221及NF-κB水平水平均显著低于治疗前,实验组以上指标明显低于对照组(P<0.05)。治疗后,实验组机体状况及生活状况较对照组高(P<0.05);两组家庭状况、情感状况、与医师关系及前列腺癌特异性生活质量评分比较差异无统计学意义(P>0.05)。治疗后,实验组机体状况及生活状况较对照组高(P<0.05);两组家庭状况、情感状况、与医师关系及前列腺癌特异性生活质量评分比较无统计学差异(P>0.05)。两组1年生存情况比较差异无统计学意义(P>0.05);实验组2年生存例数多于对照组(P<0.05)。结论:雄激素去势治疗联合多西他赛能够降低血清hk2、miR-221、NF-κB水平,改善患者生活质量及生存情况。
英文摘要:
      ABSTRACT Objective: To study the effect of androgen castration combined with docetaxel on serum levels of human kallikrein (hk2), microribonucleic acid -221 (miR-221) and nuclear transcription factor-κB (NF-κB) in patients with advanced prostate cancer. Methods: 80 patients with advanced prostate cancer treated in our hospital from September 2014 to January 2016 were selected as the research objects, and were divided into control group and experimental group according to random number table method, with 40 cases in each group. The control group was treated with androgen castration alone, while the experimental group was treated with androgen castration combined with docetaxel. The clinical efficacy, serum prostate antigen (PSA), levels of hk2, miR-221 and NF-κB, quality of life, adverse reactions and living conditions were compared between the two groups before and after treatment. Results: After treatment, the total effective rate of the experimental group was significantly higher than that of the control group (P<0.05). After treatment, the levels of serum PSA, hk2, miR-221 and NF-κB in the two groups were significantly lower than those before treatment, and the above indexes in the experimental group were significantly lower than those in the control group (P<0.05). After treatment, the physical and living conditions of the experimental group were higher than those of the control group (P<0.05). There was no significant difference in family status, emotional status, relationship with doctors and prostate cancer specific quality of life score between the two groups (P>0.05). After treatment, the physical and living conditions of the experimental group were higher than those of the control group (P<0.05). There was no significant difference in family status, emotional status, relationship with doctors and prostate cancer specific quality of life score between the two groups (P>0.05). There was no significant difference in one-year survival between the two groups (P>0.05). The number of 2-year survival cases in the experimental group was more than that in the control group (P<0.05). Conclusion: Androgen castration combined with docetaxel can reduce the levels of serum hk2, miR-221 and NF-κB, and improve the quality of life and survival of patients.
查看全文   查看/发表评论  下载PDF阅读器
关闭